Fucheng Zhang

Fucheng Zhang

Auto-generated profile, based on publicly available information

Fucheng Zhang

National Engineering Research Center for Equipment and Technology of Cold Strip Rolling, Yanshan University, Qinhuangdao, 066004, PR China

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Corrosion Science
Verified
Journal Article
Closed access
QYQiang Yu
Qiang Yu
XYXiaoyu Yang
Xiaoyu Yang
WDWangyue Dong
Wangyue Dong
QWQingfeng Wang
Qingfeng Wang
FZFucheng Zhang
Fucheng Zhang
XGXiaoyong Gu
Xiaoyong Gu

24 April 2016 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
BSBaode Shen
Baode Shen
NWNa Wu
Na Wu
CSChengying Shen
Chengying Shen
FZFucheng Zhang
Fucheng Zhang
YWYan Wu
Yan Wu
HYHailong Yuan
Hailong Yuan
The aim of this study was to develop hyperoside (Hyp) nanocrystals to enhance its dissolution rate, oral bioavailability and anti-HBV activity. Hyp nanocrystals were prepared using high pressure homogenization technique followed by lyophilization. A Box–Behnken design approach was employed for process optimization. The physicochemical properties, pharmacokinetics and anti-HBV activity in vivo of Hyp nanocrystal prepared with the optimized formulation were systematically investigated. Hyp nanocrystals prepared with the optimized formulation was found to be rod shaped with particle size of 384 ± 21 nm and PDI of 0.172 ± 0.027. XRPD studies suggested slight crystalline change in drug. Dissolution rate obtained from Hyp nanocrystals were markedly higher than pure Hyp. The nanocrystals exhibited enhanced Cmax (7.42 ± 0.73 vs. 3.80 ± 0.66 mg/L) and AUC0−t (193.61 ± 16.30 vs. 91.92 ±17.95 mg·h/L) with a 210.63% increase in relative bioavailability. Hyp nanocrystals exhibited significantly greater anti-HBV activity than Hyp. These results suggested that the developed nanocrystals formulation had a great potential as a viable approach to enhance the bioavailability of Hyp.

1 September 2020 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
FZFucheng Zhang
Fucheng Zhang
SSShuhong Su
Shuhong Su
YHYuyan Hou
Yuyan Hou
LZLipei Zhao
Lipei Zhao
ZWZhifang Wang
Zhifang Wang
LZLi Zhang
Li Zhang
This study aimed to investigate the effect of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI). 86 patients with AMI underwent primary PCI in Xinxiang central hospital between July 2015 and December 2016 were included and divided randomly into observation group and control group by the draw, with 43 patients in each group. All patients were routinely treated with dual antiplatelet therapy with aspirin plus ticagrelor. Omeprazole was used in the observation group and placebo was used in the control group. Baseline data of patients, platelet response index (PRI) ADP-induced platelet aggregation (ADP-Ag), major adverse cardiac events (MACE), and incidence of bleeding events were recorded and compared. PRI and ADP-Ag at 7 days, 1 month, and 6 months after operation in both groups were significantly lower than those in the same group before administration (p0.05). Incidence of bleeding events in the observation group was significantly lower than that in the control group (p<0.05). For AMI patients undergoing primary PCI, omeprazole can reduce the incidence of gastrointestinal bleeding without reducing the antiplatelet aggregation effect of ticagrelor or increasing the risk of MACE, which is worthy of clinical promotion.

26 February 2024 in Materials Science and Engineering: A
Verified
Journal Article
Closed access
XHXiaohong Hao
Xiaohong Hao
XSXiaowen Sun
Xiaowen Sun
TZTing Zhao
Ting Zhao
MZMengya Zhang
Mengya Zhang
YWYuefeng Wang
Yuefeng Wang
TWTiansheng Wang
Tiansheng Wang

14 July 2022 in Additive Manufacturing
Verified
Journal Article
Closed access
KCKai Cao
Kai Cao
FZFucheng Zhang
Fucheng Zhang
BWBijun Wang
Bijun Wang
YSYuning Sun
Yuning Sun
AZAhmadreza Zaeri
Ahmadreza Zaeri
RCRobert Chang
Robert Chang

16 November 2005 in Nature
Verified
Journal Article
Closed access
XXXing Xu
Xing Xu
ZZZhonghe Zhou
Zhonghe Zhou
XWXiaolin Wang
Xiaolin Wang
XKXuewen Kuang
Xuewen Kuang
FZFucheng Zhang
Fucheng Zhang
XDXiangke Du
Xiangke Du